Get started
Author

Michele Fusaroli

Observed names: Fusaroli M., Fusaroli, M., Fusaroli, Michele, Fusaroli, Michele <1994>, M Fusaroli, M. Fusaroli
Observed institutions: Uppsala Monitoring Centre, Inserm, Centre Hospitalier Universitaire de Grenoble, Centre Hospitalier Universitaire de Bordeaux, Université Grenoble Alpes, University of Bologna
ORCID: 0000-0002-0254-2212
Observed ORCID: 0000-0002-0254-2212
OpenAlex ID: A5060485627
The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and Elaboration
2024 · Michele Fusaroli, Francesco Salvo, et al. · Drug Safety · 420
The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement
2024 · Michele Fusaroli, Francesco Salvo, et al. · Drug Safety · 343
PDF
Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment
2020 · Emanuel Raschi, Michele Fusaroli, et al. · Breast Cancer Research and Treatment · 110
PDF
Skin Toxicities with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Signals from Disproportionality Analysis of the FDA Adverse Event Reporting System
2021 · Emanuel Raschi, Michele Fusaroli, et al. · American Journal of Clinical Dermatology · 63
Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database
2022 · Michele Fusaroli, Valentina Isgrò, et al. · Drug Safety · 60
PDF
Emerging Toxicities of Antibody-Drug Conjugates for Breast Cancer: Clinical Prioritization of Adverse Events from the FDA Adverse Event Reporting System
2024 · Sara Cecco, Stefano Puligheddu, et al. · Targeted Oncology · 56
PDF
Challenges and Opportunities in Accessing and Analysing FAERS Data: A Call Towards a Collaborative Approach
2023 · Valentina Giunchi, Michele Fusaroli, et al. · Drug Safety · 56
PDF
The evolving role of disproportionality analysis in pharmacovigilance
2024 · Michele Fusaroli, Emanuel Raschi, et al. · Expert Opinion on Drug Safety · 52
Serious adverse events with tocilizumab: Pharmacovigilance as an aid to prioritize monitoring in COVID‐19
2020 · Milo Gatti, Michele Fusaroli, et al. · British Journal of Clinical Pharmacology · 49
PDF
Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians
2023 · Emanuel Raschi, Simone Rossi, et al. · Drug Safety · 48
Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System
2021 · Emanuel Raschi, Michele Fusaroli, et al. · Cancers · 46
PDF
Bone fracture as a novel immune‐related adverse event with immune checkpoint inhibitors: Case series and large‐scale pharmacovigilance analysis
2021 · Daria Maria Filippini, Milo Gatti, et al. · International Journal of Cancer · 45
PDF
Enhancing Transparency in Defining Studied Drugs: The Open-Source Living DiAna Dictionary for Standardizing Drug Names in the FAERS
2024 · Michele Fusaroli, Valentina Giunchi, et al. · Drug Safety · 41
Immune Checkpoint Inhibitors and Pregnancy: Analysis of the VigiBase® Spontaneous Reporting System
2022 · Roberta Noseda, Laura Müller, et al. · Cancers · 41
Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System
2022 · Michele Fusaroli, Emanuel Raschi, et al. · The International Journal of Neuropsychopharmacology · 41
PDF
Charting and Sidestepping the Pitfalls of Disproportionality Analysis
2025 · Michele Fusaroli, Daniele Sartori, et al. · Drug Safety · 37
PDF
VigiBase: Resource Profile Update with a Summary of Global Patterns and Trends in Adverse Event Reports for Medicines and Vaccines
2026 · Judith S. Brand, Oskar Gauffin, et al. · Drug Safety · 34
PDF
Exploring the underlying mechanisms of drug‐induced impulse control disorders: a pharmacovigilance‐pharmacodynamic study
2022 · Michele Fusaroli, Valentina Giunchi, et al. · Psychiatry and Clinical Neurosciences · 33
PDF
Reporting of late-onset immune-related adverse events with immune checkpoint inhibitors in VigiBase
2024 · Roberta Noseda, Francesca Bedussi, et al. · Journal for ImmunoTherapy of Cancer · 30
PDF
Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System
2022 · Monia Sisi, Michele Fusaroli, et al. · Targeted Oncology · 27
PDF
Interpretation of Pharmacovigilance Disproportionality Analyses
2023 · Charles Khouri, Michele Fusaroli, et al. · Clinical Pharmacology & Therapeutics · 26
Modified-Chronic Disease Score (M-CDS): Predicting the individual risk of death using drug prescriptions
2020 · Marica Iommi, Simona Rosa, et al. · PLoS ONE · 24
PDF
The reporting of disproportionality analysis in pharmacovigilance: spotlight on the READUS-PV guideline
2024 · Michele Fusaroli, Francesco Salvo, et al. · Frontiers in Pharmacology · 23
PDF
Unveiling the Burden of Drug-Induced Impulsivity: A Network Analysis of the FDA Adverse Event Reporting System
2024 · Michele Fusaroli, Stefano Polizzi, et al. · Drug Safety · 23
Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System
2022 · Emanuel Raschi, Michele Fusaroli, et al. · Cancers · 22
PDF
Works count: 95
Citation count: 2,141
H-index: 23
I10-index: 44
Year
Topic
Type